Clinigen : Result of AGM and Resignation of Non-Executive Director

26 November 2020

Result of AGM and Resignation of Non-Executive Director

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, held its Annual General Meeting ('AGM') today at which all resolutions were passed. Resolutions 1-15 were passed as Ordinary Resolutions and Resolutions 14 and 15 were passed as Special Resolutions.

As previously announced in September 2020, John Hartup the Senior Independent Non-Executive Director, decided not to stand for re-election at the AGM and therefore, he has resigned as a Director of the Company with effect from today, 26 November. Consequently, Anne Hyland has been appointed as the Senior Independent Director and Alan Boyd has been appointed to engage with the workforce on behalf of the board as the designated Non-Executive Director. Both of these appointments are effective from 26 November 2020. The Nomination Committee has also started the search process for a new independent Non-Executive Director.

The voting results at the AGM are given in the table below.

			For	Against		Discretionary
						/ Withheld
Resolution	Number	%	Number	%	Number
1.	To receive the audited financial statements and the	94,363,546	100.00%	285	0.00%	89,188
	Auditors' and Directors' Reports for the year ended
	30 June 2020.
2.	To approve the Directors' Remuneration Report	89,044,191	94.28%	5,404,286	5.72%	4,542
	(other than the part containing the Directors'
	remuneration policy) for the year ended 30 June
	2020.
3.	To declare a final dividend of 5.46p per share for the year	94,451,582	100.00%	285	0.00%	1,152
	ended 30 June 2020.
4.	To re-elect Peter Allen as a Director.	82,526,572	87.38%	11,918,235	12.62%	8,212
5.	To re-elect Ian Nicholson as a Director.	92,566,213	98.02%	1,866,630	1.98%	20,176
6.	To re-elect Anne Hyland as a Director.	93,911,041	99.45%	521,802	0.55%	20,176
7.	To re-elect Alan Boyd as a Director.	79,091,727	83.93%	15,138,298	16.07%	222,994

			For		Against		Discretionary
							/ Withheld
Resolution	Number		%	Number	%	Number
8.	To re-elect Shaun Chilton as a Director.	93,543,054		99.04%	906,789	0.96%	3,176
9.	To re-elect Nick Keher as a Director.	93,258,324		98.74%	1,191,674	1.26%	3,021
10.	To reappoint PricewaterhouseCoopers LLP	91,007,732		96.36%	3,438,680	3.64%	6,607
	as auditors.
11.	To authorise the Directors to determine the auditors'	91,800,589		97.20%	2,640,554	2.80%	11,876
	remuneration.
12.	To grant the Company authority to make political	80,071,917		91.21%	7,715,738	8.79%	6,665,364
	donations.
13.	To authorise the Directors to allot shares pursuant to	93,845,132		99.36%	601,552	0.64%	6,335
	section 551 of the Companies Act 2006.
14.	To empower the Directors to disapply pre-emption	89,624,066		94.90%	4,820,119	5.10%	8,834
	rights.
15.	To empower the Directors to disapply pre-emption	88,456,906		93.66%	5,986,979	6.34%	9,134
	rights in relation to shares issued in connection with an
	acquisition or specified capital investment.

Note: As at 26 November 2020, Clinigen has 133,028,647 ordinary shares of 0.1 pence each in issue and the total number of voting rights is 133,028,647.

- Ends -
For further information, please contact:
Clinigen Group plc	Tel: +44	(0) 1283 495 010
Shaun Chilton, Group Chief Executive Officer
Nick Keher, Group Chief Financial Officer
J.P.Morgan Cazenove - Nominated Adviser & Joint Broker	Tel: +44	(0)20 7742 4000
James Mitford / Hemant Kapoor
RBC Capital Markets - Joint Broker	Tel: +44	(0)20 7653 4000
Marcus Jackson / Elliot Thomas
Instinctif Partners	Tel: [phone]
Melanie Toyne Sewell / Phillip Marriage	Email:[e-mail]

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and the Asia Pacific region.

Clinigen now has over 1,150 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long term growth regions. The Group works with 21 of the top 25 pharmaceutical companies; interacting with over 18,000 registered users across 115 countries, shipping approximately 6.5 million units in the year.

For more information on Clinigen, please visit www.clinigengroup.com.